IRVINE, CA, Aug 18, 2011 (MARKETWIRE via COMTEX) --

ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today announced its executives will present at two conferences in August and September. Both conference presentations will be webcast and will be available at www.istavision.com.

Southern California Investor Conference Monday, August 29, 2011 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) ISTA's Chief Financial Officer and Vice President Corporate Development Lauren Silvernail will make a formal presentation on the marketed products, pipeline and corporate strategy.

Stifel Nicolaus Annual Healthcare Conference Wednesday, September 7, 2011 at 2:40 p.m. Eastern Time ISTA's President and Chief Executive Officer Vicente Anido, Jr., Ph.D., will conduct a fireside chat with Stifel analyst Annabel Samimy on the company's competitive position and corporate outlook, after which he will also respond to questions from the on-site audience.

To access the live audio broadcast of the presentations, or the subsequent archived recording, log onto http://www.istavision.com/investors.html. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

ABOUT ISTA PHARMACEUTICALS

ISTA Pharmaceuticals, Inc. is a fast growing and the fourth largest branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. ISTA currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The Company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain, and nasal allergies. Headquartered in Irvine, California, ISTA generated revenues of $156.5 million in 2010. For additional information about ISTA, please visit the corporate website at www.istavision.com. 

Contacts
Investor Relations Contacts at ISTA Pharmaceuticals, Inc.:
Lauren Silvernail
949-788-5302
lsilvernail@istavision.
Jeanie Herbert
949-789-3159
jherbert@istavision.
Media and Additional Investor Relations Contacts at Burns McClellan:
Justin Jackson
(Media)
212-213-0006
jjackson@burnsmc.
Juliane Snowden
(Investor Relations)
212-213-0006
jsnowden@burnsmc.

SOURCE: ISTA Pharmaceuticals 

mailto:lsilvernail@istavision.mailto:jherbert@istavision.mailto:jjackson@burnsmc.mailto:jsnowden@burnsmc.